Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Frequently asked questions
What sector does Entrada Therapeutics Inc (TRDA) operate in?
Entrada Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Entrada Therapeutics Inc (TRDA) current stock price?
As of the latest data, Entrada Therapeutics Inc stock price is $4.75, with a previous close of $4.41. Entrada Therapeutics Inc gained $0.34 in the last trading session, representing a 7.71% increase.
What is Entrada Therapeutics Inc (TRDA) current market capitalization?
Entrada Therapeutics Inc market cap is approximately 184.95 million.
What is Entrada Therapeutics Inc (TRDA) Earnings Per Share (EPS)?
The trailing EPS is -$3.96, and the forward EPS is -$3.01.
What is Entrada Therapeutics Inc (TRDA) EBITDA?
Entrada Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -41.89 million.
Does Entrada Therapeutics Inc (TRDA) pay dividends?
No. Entrada Therapeutics Inc does not pay a dividend.
How did Entrada Therapeutics Inc (TRDA) perform in its most recent earnings report?
In the last report (June 30, 2026), Entrada Therapeutics Inc posted an EPS surprise of 12.93% and a revenue surprise of -59.81%.
When is Entrada Therapeutics Inc (TRDA) next earnings report?
Entrada Therapeutics Inc is expected to release its next earnings report on September 30, 2026.
What is Entrada Therapeutics Inc (TRDA) beta (volatility) score?
Entrada Therapeutics Inc has a beta of -0.238, indicating lower volatility than the overall market.
